Researchers aim to combine psilocybin and cannabis in a single medical treatment

The company, CaaMTech, received its first patent in support of research in 2021. An article published Wednesday on the Greenstate website explains that the company is «developing pharmaceutical drugs for mental illnesses such as depression and obsessive-compulsive disorder» and is «currently investigating the therapeutic value of psilocybin in combination with cannabinoids».

«Through its research, CaaMTech has isolated derivatives of psilocybin, cannabinoids and terpenes,» explains Greenstate.

Activating psychedelics and cannabinoids

Andrew Chadeayne, founder and CEO of CaaMTech, said that «from day one, the company's goal has been to integrate as much of CaaMTech's scientific innovation as possible into its intellectual property portfolio, as we develop the next generation of psychedelic drugs».

«The acceptance of our first patent application has given a burst of energy to the team that has worked steadily over the past four years to bring it to the finish line,» Chadeayne said in the announcement. «While there are still hundreds of applications to process, this is an excellent start.»

«Strong patent protection and basic research give our drugs the fundamental support they need to pass clinical trials and become FDA-approved drugs,» he added.

Compositions and methods comprising a psilocybin derivative« cover (among other things) the synergistic modulatory effects of psilocybin and psilocybin derivatives. cannabinoids on serotonin receptor activation when administered in conjunction with a serotonin agonist. In simpler terms, CaaMTech has demonstrated that cannabinoids act synergistically with psychedelic tryptamines to produce their effects. In so doing, CaaMTech has demonstrated the potential of two drugs once declared by the US federal government to have «no known medical value» to treat some of the world's most challenging mental health problems.

The announcement states that «the notice of allowance [from the U.S. Patent and Trademark Office (USPTO)] is a watershed moment for CaaMTech's intellectual property division, which has filed more than 100 additional patent applications since the 2017 filing.»

«Authorization is the last hurdle in the examination process before a patent is granted,» says the press release.

Since the patent was approved in 2021, Greenstate reports that «CaaMTech has shared results related to 4-PrO-DMT as a new synthetic alternative to psilocybin, among other things.»

«Separate efforts can complement this work, such as SABI Mind's research survey covering a myriad of topics, such as the general acceptance or disdain for synthetic alternatives to compounds such as psilocybin. These measures, along with the policy work, create broader pathways for patients seeking trustworthy, science-based psychedelic therapies,» the media outlet reported.

The development of a treatment will not be easy because of «serious obstacles to the creation of a combination compound».

«Cannabinoids and psychedelics act on different receptors in the brain. Cannabinoids such as THC bind primarily to the CB1 cannabinoid receptor ; CBC binds mainly to the CB2 receptor. Psychedelics such as psilocybin bind primarily to serotonin 5-HT2A receptors,» says the journal.

«But research has shown that the cannabinoid CBD can bind to serotonin and that, when serotonin is associated with an CB2 cannabinoid receptor, The combination of the two can do things that neither receptor can do alone... Buoyed by the potential of the combined compound, the medical cannabis community is increasingly enthusiastic. For example, cannabis combined with psychedelics has been shown to dramatically reduce tumors in breast cancer».

CaaMTech, based in Issaquah, Washington, bills itself as «the leading drug discovery and lead optimization company focused on developing psychedelic drugs that meet the standards of modern medicine».